“We will cure cancers and save lives with our innovative and widely accessible immunotherapies.”
Tessa’s story started over 20 years ago, when Dr. Malcolm Brenner, our co-founder, and his team at Baylor College of Medicine embarked on a journey to better understand and harness the body’s natural anti-viral immune response. Their research led to the development of our platform technology – Virus-Specific T cells (VST).
Initial VST trials held promising results – including TT10 Phase II trial at National Cancer Centre Singapore (NCCS) which produced the best published 2-year survival data in patients with advanced NPC. This set the stage for the pivotal Phase III trial, which is the world’s largest T cell therapy trial for any cancer indication with 330 patients across 30 hospitals and 4 labs in 5 countries.
Today, Tessa has expanded our pipeline to target multiple cancer indications, building next generation technologies on our core VST platform. We are proud to be spearheading innovation in the field of cancer immunotherapy for solid tumors and are committed to working towards our vision of a world without untreatable cancers.